Royal Marsden NHS Foundation Trust: Nearly One Third of Patients With Advanced Melanoma Saw Tumours Disappear Completely After Receiving TIL Therapy Plus Pembrolizumab Immunotherapy
October 24, 2026
October 24, 2026
LONDON, England, Oct. 24 (TNSxrep) -- The Royal Marsden National Health Service Foundation Trust issued the following news:
* * *
Nearly one third of patients with advanced melanoma saw tumours disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy
An early-stage clinical trial suggests combining two types of immunotherapy at the start of treatment, lifileucel TIL therapy and an immune checkpoint inhibitor, may lead to deep and lo . . .
* * *
Nearly one third of patients with advanced melanoma saw tumours disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy
An early-stage clinical trial suggests combining two types of immunotherapy at the start of treatment, lifileucel TIL therapy and an immune checkpoint inhibitor, may lead to deep and lo . . .